The prevalence of major depression in stage 5 chronic kidney disease (CKD) varies between 14 and 30%. Patients with CKD who are depressed have a worse quality of life, are hospitalized more often and die sooner than those who are not depressed. Antidepressant drugs are effective in the general population, but whether they improve outcomes in CKD is uncertain. Drug pharmacokinetics are altered in CKD, which may necessitate dose adjustment. We aimed to systematically review available evidence of the pharmacokinetics, efficacy and safety of antidepressant drugs when used in patients with CKD3 to CKD5 (CKD3-5). This is a systematic review of randomized clinical trials and observational studies examining antidepressants in patients with CKD3-5, regardless of whether or not patients are on dialysis. Through comprehensive searches of seven databases, we identified all studies examining pharmacokinetic properties or clinical outcomes in patients with CKD3-5. When it comes to prescription antidepressants, patients often try different drugs before settling on one that works best for them. Lexapro and Zoloft are both prescription SSRI antidepressants prescribed to treat depression and anxiety. They work by restoring the balance of neurotransmitters like serotonin. The difference is that Zoloft can treat several additional symptoms, but Lexapro has a faster release time. Lexapro and Zoloft also have different side effects. Common: Confusion, difficulty concentrating, euphoria, suicidal thoughts, decreased sex drive & ability. Rare: aggressive behavior, high BP, heart attack, blood clots, very rapid heartbeat, slow heartbeat, hemorrhage, kidney failure, seizures.
Chronic Kidney Disease. PHYSICIAN/NURSE. Dosing adjustment in renal failure. Sertraline. No adjustment. SD 50 mg/day. SD 25 mg/day. SD 25 mg/day. I have anxiety, I want to take Zoloft, any future side affects like, heart issues, liver or kidney damage. Eye is more I have anxiety, I want to take Zoloft, any future side affects like, heart issues, liver or kidney damage.